EA201892462A1 - Фенольное соединение и его комбинация с бензодиазепином, конденсированным с 1,4-дигидропиридином, для лечения поражений центральной нервной и сосудистой систем - Google Patents

Фенольное соединение и его комбинация с бензодиазепином, конденсированным с 1,4-дигидропиридином, для лечения поражений центральной нервной и сосудистой систем

Info

Publication number
EA201892462A1
EA201892462A1 EA201892462A EA201892462A EA201892462A1 EA 201892462 A1 EA201892462 A1 EA 201892462A1 EA 201892462 A EA201892462 A EA 201892462A EA 201892462 A EA201892462 A EA 201892462A EA 201892462 A1 EA201892462 A1 EA 201892462A1
Authority
EA
Eurasian Patent Office
Prior art keywords
condensed
treatment
central nervous
benzodiazepine
diseases
Prior art date
Application number
EA201892462A
Other languages
English (en)
Other versions
EA037951B1 (ru
Inventor
Эстаел Очоа Родригуес
Ямила Вердеция Рейес
Яниер Нунез Фигуэредо
Дженей Рамирез Санчез
Майлин Вонг Гуерра
Луис Артуро Фонзека Фонзека
Гилберто Лазаро Пардо Андреу
Клаудиа Аманда Канаан-Хаден Наварро
Абель Мондело Родригес
Педро Жильберто Барзага Фернандес
Никте Гонзалез Алфонсо
Рене Делгадо Хернандез
Алехандро Саул Падрон Якис
Original Assignee
Универсидад Де Ла Гавана
Сентро Де Инвестигасион И Десаррольо Де Медикаментос Сидем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Универсидад Де Ла Гавана, Сентро Де Инвестигасион И Десаррольо Де Медикаментос Сидем filed Critical Универсидад Де Ла Гавана
Publication of EA201892462A1 publication Critical patent/EA201892462A1/ru
Publication of EA037951B1 publication Critical patent/EA037951B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Изобретение относится к химии, фармации и, в частности, к приготовлению лекарственных препаратов из производных фенольных или полифенольных соединений, комбинированных с трициклическими системами соединений класса бензодиазепинов, конденсированных с производными 1,4-дигидропиридинов, воздействующих на центральную нервную и сосудистую системы. Эти фармацевтические композиции демонстрируют ГАМК-эргическое, антиглутаматергическое, модулирующее кальциевые каналы, митопротекторное, антиокислительное, антивоспалительное и антиапоптотическое действие, что можно применять в лечении сердечно-сосудистых, цереброваскулярных, нейродегенеративных, нейропсихиатрических и неврологических заболеваний.
EA201892462A 2016-05-04 2017-05-03 Фенольное соединение и его комбинация с бензодиазепином, конденсированным с 1,4-дигидропиридином, для лечения поражений центральной нервной и сосудистой систем EA037951B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2016000059A CU24576B1 (es) 2016-05-04 2016-05-04 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular
PCT/CU2017/050003 WO2017190714A1 (es) 2016-05-04 2017-05-03 Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular

Publications (2)

Publication Number Publication Date
EA201892462A1 true EA201892462A1 (ru) 2019-07-31
EA037951B1 EA037951B1 (ru) 2021-06-11

Family

ID=60202803

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892462A EA037951B1 (ru) 2016-05-04 2017-05-03 Фенольное соединение и его комбинация с бензодиазепином, конденсированным с 1,4-дигидропиридином, для лечения поражений центральной нервной и сосудистой систем

Country Status (19)

Country Link
US (1) US10722491B2 (ru)
EP (1) EP3453704B1 (ru)
JP (1) JP6997995B2 (ru)
KR (1) KR102416478B1 (ru)
CN (1) CN109476627B (ru)
AR (1) AR108370A1 (ru)
AU (1) AU2017259749C1 (ru)
BR (1) BR112018072579B1 (ru)
CA (1) CA3023073C (ru)
CL (1) CL2018003114A1 (ru)
CO (1) CO2018011927A2 (ru)
CU (1) CU24576B1 (ru)
EA (1) EA037951B1 (ru)
ES (1) ES2878579T3 (ru)
MX (1) MX2018013422A (ru)
PH (1) PH12018502327A1 (ru)
SG (1) SG11201809843SA (ru)
WO (1) WO2017190714A1 (ru)
ZA (1) ZA201808161B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20160058A7 (es) 2016-05-04 2017-12-08 Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular
CA3164091A1 (en) * 2019-12-26 2021-07-15 Centro De Investigacion Y Desarrollo De Medicamentos Cidem Use of a benzodiazepine derivative and method of treatment of traumatic brain injury
CU20190114A7 (es) 2019-12-26 2021-08-06 Centro De Investig Y Desarrollo De Medicamentos Cidem Combinación para simultáneamente incrementar la eficacia analgésica de la morfina y reducir su dependencia física

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281714A (en) 1990-08-16 1994-01-25 American Home Products Corporation N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase
MX9204939A (es) 1991-09-06 1993-03-01 American Home Prod Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
ES2074770T3 (es) 1992-07-17 1995-09-16 Biogal Gyogyszergyar Procedimiento de preparacion de derivados de 1,3-dioxano-4,6-diona.
JPH11180975A (ja) 1997-10-13 1999-07-06 Chemiprokasei Kaisha Ltd アミノメチレンジオキサン誘導体、その製造方法および用途
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP2007063444A (ja) * 2005-08-31 2007-03-15 Tdk Corp 錯化合物及びこれを用いた光記録媒体

Also Published As

Publication number Publication date
JP2019516791A (ja) 2019-06-20
JP6997995B2 (ja) 2022-02-04
BR112018072579B1 (pt) 2024-02-20
WO2017190714A1 (es) 2017-11-09
ES2878579T3 (es) 2021-11-19
AR108370A1 (es) 2018-08-15
US10722491B2 (en) 2020-07-28
MX2018013422A (es) 2019-08-16
KR102416478B1 (ko) 2022-07-04
CN109476627A (zh) 2019-03-15
KR20210025138A (ko) 2021-03-09
AU2017259749C1 (en) 2021-12-02
EP3453704B1 (en) 2021-06-16
CU20160059A7 (es) 2017-12-08
US20190133996A1 (en) 2019-05-09
SG11201809843SA (en) 2018-12-28
EA037951B1 (ru) 2021-06-11
ZA201808161B (en) 2021-10-27
CL2018003114A1 (es) 2019-06-14
AU2017259749A1 (en) 2018-12-20
CA3023073C (en) 2022-08-30
CU24576B1 (es) 2022-02-04
BR112018072579A2 (pt) 2019-02-19
EP3453704A1 (en) 2019-03-13
CN109476627B (zh) 2021-06-15
CO2018011927A2 (es) 2019-02-08
CA3023073A1 (en) 2017-11-09
AU2017259749B2 (en) 2021-08-19
PH12018502327A1 (en) 2019-09-02

Similar Documents

Publication Publication Date Title
CL2018003105A1 (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos.
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002745A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
EA201892462A1 (ru) Фенольное соединение и его комбинация с бензодиазепином, конденсированным с 1,4-дигидропиридином, для лечения поражений центральной нервной и сосудистой систем
WO2017027810A3 (en) Compositions and methods that promote the hypoxia response for treatment of mitochondrial dysfunction and oxidative stress disorders
EA201592024A1 (ru) Замещенные 5-(3,5-диметилизоксазол-4-ил)-индолин-2-оны
CL2019002744A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
EP3412669A4 (en) TRICYCLIC COMPOUND FOR PROTEIN INHIBITOR CONTAINING BROMODOMAINE AND PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF
CL2019003294A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
UY37221A (es) Derivados de feniltriazol sustituidos con amida y usos de estos
WO2016077656A3 (en) Methods and compositions for inhibition of bromodomain and extraterminal proteins
CL2018000783A1 (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
EA201691539A1 (ru) 2,7-диазаспиро[3.5]нонановые соединения
WO2017075264A8 (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
EA033297B1 (ru) Терапевтические и питательные композиции для функциональных нарушений работы пищеварительной системы
EA201692051A1 (ru) Арилзамещенные гетероциклилсульфоны
CU20160142A7 (es) Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4 dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular
WO2015104298A3 (de) Polyphenol-konjugate